Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Capital Expenditures (2017 - 2025)

Protagonist Therapeutics' Capital Expenditures history spans 9 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 258.36% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 3356.52%, while the annual FY2025 figure was $1.6 million, 3356.52% up from the prior year.
  • Capital Expenditures for Q4 2025 was $1.6 million at Protagonist Therapeutics, up from -$1.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.6 million in Q4 2025 and bottomed at -$1.3 million in Q3 2025.
  • The 5-year median for Capital Expenditures is $166500.0 (2022), against an average of $207050.0.
  • The largest YoY upside for Capital Expenditures was 3915.15% in 2025 against a maximum downside of 275.32% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $1.1 million in 2021, then plummeted by 93.5% to $70000.0 in 2022, then skyrocketed by 765.71% to $606000.0 in 2023, then plummeted by 264.85% to -$999000.0 in 2024, then surged by 258.36% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Capital Expenditures are $1.6 million (Q4 2025), -$1.3 million (Q3 2025), and $1.3 million (Q2 2025).